[The current treatment of Parkinson's disease].
D000547:Amantadine / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage; D004338:Drug Combinations; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D001523:Mental Disorders / Q000139:chemically induced; D009069:Movement Disorders / Q000139:chemically induced; D009490:Neurosecretory Systems / Q000503:physiopathology; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D026741:Physical Therapy Modalities; D011736:Pyridoxine / Q000627:therapeutic use; D013238:Stereotaxic Techniques
D000929:Antidepressive Agents, Tricyclic; D004338:Drug Combinations; D006633:Histamine Antagonists; D010276:Parasympatholytics; D007980:Levodopa; D004295:Dihydroxyphenylalanine; D000547:Amantadine; D011736:Pyridoxine
Le traitement actuel de la maladie de Parkinson